Better symptom control for longer periods of time and with fewer doses:

- Amneal Pharmaceuticals is expected to resubmit their application for a pill containing both immediate- and extended-release levodopa and carbidopa, similar to the currently available brand-name Rytary, but reformulated for potentially better absorption and longer lasting effects.
- Pharma Two B is expected to submit a New Drug Approval application for its drug that combines two approved Parkinson's medications (pramipexole, the generic of Mirapex, and rasagiline, the generic of Azilect) in low doses to potentially be more effective in reducing symptoms.

THE MICHAEL J. FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Grand Central Station, P.O. Box 4777
New York, NY 10163
michaeljfox.org/newera

THE MICHAEL J. FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Our Most Ambitious Roadmap Yet

Needs Your Support

We experienced an extraordinary moment for Parkinson's research in 2023 — a discovery that is the catalyst for more targeted treatments, earlier intervention and, ultimately, prevention. With your continued partnership, we can boldly move in new, strategic directions to turn this breakthrough into urgently needed solutions for people and families with Parkinson's disease (PD).

These findings will propel today's Parkinson's pipeline of nearly 200 active trials testing different therapies.

They include therapies to slow or stop disease progression and improve symptom management — a challenging unmet need for people living with Parkinson's. Potential approvals or (re)submissions to the U.S. Food and Drug Administration for symptomatic therapies in 2024 include:

Under-the-skin continuous daily infusion for people with advanced PD whose symptoms aren't well controlled by oral medication:

- Supernus Pharmaceutical Inc. resubmitted their application for infused apomorphine to lessen total daily "off" time (when symptoms return).
- AbbVie is expected to resubmit a revised application for a new formulation of infused levodopa.
- Neuroderm is expected to submit an application for its liquid levodopa/carbidopa — which received MJFF funding for early studies — to provide consistent medication levels for symptom relief.

Building on more than two decades of funding biomarker work,

The Michael J. Fox Foundation (MJFF) has a plan to leverage the new biomarker tool (the alpha-synuclein seeding amplification assay, or SAA) and transform drug development within the next three to eight years:



Goal Where we are going:

- Deepen our knowledge of SAA as a biomarker across the PD continuum, including when PD first occurs in the body
- Establish a staging system for PD to determine where people are in the biological progression of the disease
- Improve our understanding of advancing PD, including the role of other biomarkers in cognitive symptoms
- Launch the first PD prevention trial

Action How we'll get there:

- Extend SAA testing to all PPMI participants and investigate new PD biomarkers and their correlation to SAA
- Expand enrollment in PPMI, collect data from people at every stage to define how PD biology relates to risk, onset and progression
- Explore the risk of later symptoms (cognitive changes, gait dysfunction) in PPMI participants and improve our understanding of amyloid-tau biology within PD
- Launch Path to Prevention trial within PPMI to establish proof-of-principle for trials testing potential therapies to prevent PD entirely